Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Smith & Nephew PLC Director's Dealing 2023

May 19, 2023

4588_dirs_2023-05-19_a9906d88-54d4-4e64-8aa3-eb9da433d891.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 0848A

Smith & Nephew Plc

19 May 2023

SMITH & NEPHEW PLC

19 May 2023

NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.

Reason for the notification
Initial notification /Amendment Initial notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Name Smith & Nephew plc
LEI 213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument Smith & Nephew plc ordinary shares of USD 0.20 each
Identification code ISIN: GB0009223206
Nature of the transaction Purchase of ordinary shares through the Company's Dividend Re-Investment Plan following the 2022 final dividend payment on 17 May 2023.
Date of Transaction 2023 - 05 - 17
Place of Transaction London Stock Exchange (XLON)
Name

(Position)
Director / PDMR Price Volume Aggregated information Total Ordinary Share Holding following the transaction * Total Ordinary Share Holding as a % of the Company's ISC following the transaction *
Helen Barraclough

(Group General Counsel and Company Secretary)
PDMR £13.13964 406.16316 N/A Single Transaction 29,139.41087 0.00332%
Bradley Cannon

(Global Orthopaedics)
PDMR £13.13964 365.26743 N/A Single Transaction 118,184.64237 (including 3,599.09977 in ADS') 0.01347%
Paul Connolly

(President Global Operations)
PDMR £13.13964 102.08593 N/A Single Transaction 7,400.08593 0.00084%
Phil Cowdy

(Chief Corporate Development & Corporate Affairs Officer)
PDMR £13.13964 195.14937 N/A Single Transaction 49,196.14246 0.00561%
Myra Eskes

(President APAC & Global Service)
PDMR £13.13964 855.60779 N/A Single Transaction 62,021.97554 0.00707%
Simon Fraser

(President AWM and Global Commercial Operations)
PDMR £13.13964 707.85737 N/A Single Transaction 51,311.72617 0.00585%
Mizanu Kebede

(Chief Quality & Regulatory Affairs Officer)
PDMR £13.13964 54.14835 N/A Single Transaction 5,530.80779 (including 802.82972 in ADS') 0.00063%
Elga Lohler

(Chief HR Officer)
PDMR £13.13964 285.19156 N/A Single Transaction 144,683.19156 (including 3,015.00000 in ADS') 0.01649%
Deepak Nath

(Chief Executive Officer)
Director £13.13964 1,367.8228 N/A Single Transaction 99,151.82280 0.01130%
Vasant Padmanabhan

(President Research & Development)
PDMR £13.13964 264.13931 N/A Single Transaction 100,353.13931 0.01143%
Alison Parkes

(Chief Compliance Officer)
PDMR £13.13964 30.61803 N/A Single Transaction 4,679.11972 (including 1,040.32795 in ADS') 0.00053%
Scott Schaffner

(President Sports Medicine)
PDMR £13.13964 763.54875 N/A Single Transaction 68,095.98048 (including 1,927.12679 in ADS') 0.00776%

* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.

Sarah Carne  

Deputy Company Secretary

Smith & Nephew plc

Tel:  +44 (0)1923 477100

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFESELIALIV